Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 79, Issue 1, Pages 56-71
Publisher
Wiley
Online
2013-10-18
DOI
10.1111/bcp.12258
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates
- (2013) Peter L. Bonate et al. AAPS Journal
- Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
- (2013) R. L. Korn et al. CLINICAL CANCER RESEARCH
- Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling
- (2013) M L Maitland et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Model-Based Drug Development in Oncology: What’s Next?
- (2013) R Bruno et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer
- (2013) Laurent Claret et al. JOURNAL OF CLINICAL ONCOLOGY
- Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical Relevance
- (2012) Markus Joerger AAPS Journal
- Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial
- (2012) Andrew Stein et al. BMC CANCER
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
- (2012) Brendan C. Bender et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy
- (2012) B. Ribba et al. CLINICAL CANCER RESEARCH
- Models for Disease Progression: New Approaches and Uses
- (2012) D R Mould CLINICAL PHARMACOLOGY & THERAPEUTICS
- Simulations Using a Drug–Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non–Small-Cell Lung Cancer
- (2012) L Claret et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making
- (2012) Jun Yang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
- (2011) Ron J. Keizer et al. AAPS Journal
- Understanding the time course of pharmacological effect: a PKPD approach
- (2011) Daniel F. B. Wright et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia
- (2011) Emma K. Hansson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer
- (2011) N. Frances et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
- (2011) Digant Gupta et al. Nutrition Journal
- Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint
- (2010) Stephen B. Duffull et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer
- (2010) Laurent Claret et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients
- (2010) Jian-Feng Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
- (2010) W. D. Stein et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers
- (2010) A Lindauer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model
- (2010) Angelica Linnea Quartino et al. INVESTIGATIONAL NEW DRUGS
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
- (2010) Ron J. Keizer et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Predictive Value of Modeled AUCAFP-hCG, a Dynamic Kinetic Parameter Characterizing Serum Tumor Marker Decline in Patients With Nonseminomatous Germ Cell Tumor
- (2010) Benoit You et al. UROLOGY
- Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information
- (2009) Johan E. Wallin et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure
- (2009) S. E. DePrimo et al. CLINICAL CANCER RESEARCH
- Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia
- (2009) LE Friberg et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
- (2009) Y Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies
- (2009) R Bruno et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
- (2009) Laurent Claret et al. JOURNAL OF CLINICAL ONCOLOGY
- A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis
- (2009) Pankaj Gupta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy
- (2009) Benoit You et al. PROSTATE
- A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients
- (2008) L.-S. Tham et al. CLINICAL CANCER RESEARCH
- A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine
- (2008) E Hénin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now